ControlFlow
Restoring confidence and independence for women living with urinary incontinence.
ControlFlow is a smart intraurethral device designed to enable controlled urination — without external collection bags, indwelling catheters, or invasive surgery. Developed by TIKI100, ControlFlow puts women back in control of their daily lives with a discreet, technology-enabled approach to bladder management.
Request Investor Deck
The Problem
Urinary Incontinence Affects Over 200 Million Women Worldwide
Urinary incontinence is one of the most prevalent yet underaddressed conditions in women's health. Its incidence increases significantly with age, affecting an estimated 1 in 3 women over 45 and becoming near-universal among elderly and neurologically affected populations. Despite its scale, the condition remains deeply stigmatized and chronically undertreated.
Women living with urinary incontinence face daily compromises — limiting physical activity, social engagement, and professional participation. The psychological toll is substantial: loss of dignity, persistent anxiety, and a reduced sense of autonomy. Current management options address symptoms superficially but rarely restore true independence.
200M+
Women Affected
Globally living with urinary incontinence
1 in 3
Women Over 45
Experience some form of incontinence
$200B+
Annual Market
Global incontinence management spend
70%
Underdiagnosed
Estimated share who never seek treatment
Current Limitations
Why Current Options Fall Short
The existing standard of care offers fragmented, incomplete solutions. Each approach carries meaningful clinical or quality-of-life limitations — leaving a significant unmet need for a comprehensive, patient-centered alternative.
Pads & Diapers
Widely used but fundamentally passive. They manage leakage after the fact, offering no control over bladder function. Associated with skin irritation, odor, and daily inconvenience — they are a coping mechanism, not a solution.
Medications
Pharmacological treatments target overactive bladder but demonstrate variable efficacy across patient populations. Side effects limit long-term adherence and suitability.
Catheters
Indwelling or intermittent catheters provide functional drainage but introduce significant discomfort and elevated risk of urinary tract infections.
Surgery
Surgical interventions address structural causes but are invasive, irreversible in some forms, and not appropriate for all patients — particularly the elderly or medically complex.
Our Approach
A Discreet, Smart Solution for Daily Control
ControlFlow is a connected intraurethral device that enables user-controlled urination through a simple mobile interface. Designed around the real-world needs of women managing incontinence daily, it bridges the gap between passive symptom management and genuine functional independence.
The platform is built with clinical rigor and patient experience at its core — engineered to be unobtrusive, technology-enabled, and developed with safety as a primary design principle.
Designed for Discretion
A form factor that integrates seamlessly into daily life — no external hardware, no visible equipment, and no disruption to normal routine.
Non-Implantable
ControlFlow does not require surgical implantation. It is designed for patient-managed use, preserving the option for discontinuation and reducing procedural risk.
Technology-Enabled Control
A connected mobile interface gives patients agency over their own bladder function — shifting control from condition to user, on their schedule.
Built with Safety in Mind
Infection-risk mitigation is a foundational design consideration. Material selection, use protocols, and device architecture reflect an evidence-based approach to urological safety.
Impact
Restoring Dignity. Enabling Independence.
"For millions of women, urinary incontinence is not a minor inconvenience — it is a condition that silently reshapes identity, limits freedom, and erodes confidence. ControlFlow is designed to change that."
The measure of ControlFlow's success is not a clinical endpoint alone — it is the woman who returns to the gym, the professional who attends the full conference, the grandmother who plays with her grandchildren without anxiety. It is the shift from passive management to active, technology-enabled control.
TIKI100 is building a solution that treats women not as patients to be managed, but as individuals deserving of the same standard of care, dignity, and technological innovation that defines modern medicine. ControlFlow is the first step in that commitment.
From Passive to Active
Shifting care from reactive management to user-controlled independence.
Quality of Life
Designed to restore social, professional, and personal freedom.
Patient-Centered
Built around the lived experience of women managing incontinence daily.
Credibility
Backed by Israel's Leading Innovation Ecosystem
TIKI100 is building ControlFlow within one of the world's most rigorous and respected medtech innovation environments. Our institutional backing reflects both the clinical significance of the problem we are addressing and the credibility of our approach to solving it.
SouthUp Incubator
TIKI100 is a proud portfolio company of SouthUp, a leading technology incubator located in the Gaza Envelope region of Israel. SouthUp supports deep-tech and medtech startups with hands-on operational expertise, strategic networks, and a mission-driven investment thesis focused on resilience and innovation.
Israel Innovation Authority
TIKI100 is a recipient of a Pre-Seed Grant from the Israel Innovation Authority (IIA) — Israel's primary government body for supporting R&D-intensive technology companies. IIA backing signals rigorous technical and commercial validation at the earliest stage of company formation.
The Team
Leadership Built for This Challenge
The TIKI100 team combines clinical insight, medtech engineering experience, and entrepreneurial execution. We are a multidisciplinary group united by a shared conviction: that women's health deserves smarter, more dignified solutions — and the technical rigor to deliver them.
Dr. Avi Segev
Founder & CEO
Dr. Hadas Shatz-Azoulay
Deputy CEO & COO
Dr. Shiri Yaniv
Head of Business Development
Eng. Adi Ickowicz,
Head of Regulatory & Strategy
Eng. Ricardo Schleifer
Business Advisor
Prof. Adi Weintraub
Urogynecology & Pelvic Floor Medicine Specialist. Soroka Medical Center
Prof. Anna Padua
Director of Urogynecology and Pelvic Floor Service, Chaim Sheba Medical Center
Contact
Let's Talk
TIKI100 is actively raising its seed round and building strategic partnerships with clinical institutions, women's health organizations, and medtech ecosystem players. We welcome conversations with aligned investors, clinicians, and distribution partners who share our commitment to advancing women's health.
Investor Inquiries
Request the full investor deck, financial projections, and development roadmap. Schedule a call with the founding team.
Clinical Partners
Explore opportunities for clinical advisory roles, trial site collaboration, or research partnership with TIKI100.
ControlFlow is under development and has not yet received regulatory approval for commercial sale in any market. All information provided on this page is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase any securities. Proprietary technical details, regulatory classifications, and engineering specifications are withheld and available only under NDA to qualified parties.